Brief: Addex Therapeutics Starts Phase 2B/3 Study With Dipraglurant For Dyskinesia

Addex Therapeutics

29/06/2021 06:04

June 29 (Reuters) - ADDEX THERAPEUTICS LTD  ADXN.S :
    * ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH
DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE

Source text for Eikon:  ID:nGNE4ll13m 
Further company coverage:  ADXN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))